E & E Communications in Review: Sales & Marketing Excerpts.
When I sift through all the information I've identified the following:
-- Walmart retail stores
-- MundiPharma RecoveryRx and 20-30 additional countries
-- Partner # 1: major company that has a primary interest in plantar fasciitis.
-- Partner # 2.a.: Channel Partner: global player in the orthopedic devices industry
-- Partner # 2.b.: orthopedic line to be sold to performance health and other drug distributors. DEAL DONE PRIOR TO 9-16-2020
-- Partner # 3: prescription (post-operative pain conditions)
-- Distributor of chiropractic products in US with 70,000 chiropractors in the US. DEAL DONE PRIOR TO 9-16-2020
-- An American multinational health care services company to place ActiPatch in 1,000 independently owned stores
-- Veteran Owned Small Business organizations
WHAT WASN'T MENTIONED:
CVS
B.Braun
NHS
The signed deals in place with large pharmaceutical companies in Russia and Ukraine
"Try and Tell" Marketing program
E & E Communications Mon, Jun 17, 2019
Keith Nalepka – VP of Sales and Marketing, is going to attend and invitation-only event from Walmart for its annual supplier’s orientation meeting this week. ActiPatch is one of 30 products that were selected by the pain category manager at Walmart.
We are currently in discussions with another MundiPharma subsidiary to expand our successful relationship with Mundipharma Australia/New Zealand/South East Asia, which would raise the total coverage under Mundipharma to territories 20 countries.
E & E Communications Wed, Jul 10, 2019
I am in discussions with some of my former Purdue associates who are currently calling on hospitals and ambulatory surgery centers to sell the RecoveryRx for the 25 million US surgeries.
I am also confident that we can get Mundipharma and our other distributors in addition to ActiPatch® for musculoskeletal pain to market and sell RecoveryRx.
Nalepka explained that the Company is in discussions with two groups to license the products for US and international sales.
At the recent meeting with Walmart, they indicated said that if strong sales can be demonstrated online, then in-store sales can be discussed in August.
E & E Communications Mon, Sep 16, 2019
We are also finalizing product packaging configuration with the largest distributor of chiropractic products in US. They have access to 80% of the 70,000 chiropractors in the US who treat 35 million patients annually.
We remain in discussions with several marketers of wraps and braces for the sports and retail markets. The next several months are key to obtain inclusion in the 2020 sales plans and shelf space.
US OTC Sales and Marketing Partnership
We will begin meeting with our partner to design and finalize the development of our orthopedic line to be sold into performance health and other drug distributors. This has been finalized and we are looking forward towards immediate retail sales of which we have gotten our first purchase order from today.
E & E Communications Mon, Nov 4, 2019
We have actively re-engaged discussions with companies who previously expressed interest in establishing commercial partnerships with BioElectronics, in the US. We have had a face to face discussion with a major company that has a primary interest in plantar fasciitis. The discussion went very well, with further meetings already scheduled.
We have also scheduled calls with two large players in the commercial space.
One of our channel partners has finalized a deal with an American multinational health care services company to place ActiPatch in 1,000 independently owned stores and launch under an initiative for alternative pain therapies. This program is set to launch late in the first quarter of 2020.
Our channel partner has expertise in creating custom orthopedic appliances and has been asked by a global provider of high-quality orthopedic devices to develop a product for proposed post-operative use, and two other anatomical sites which fall under existing OTC indications.
We have also begun recruiting established Veteran Owned Small Business organizations that are currently selling medical products to the Veterans Administration Health System. At this time, we have signed agreements with two organizations.
E & E Communications Mon Mon, Dec 16, 2019
In early November we entered into an NDA with one such partner. The NDA discussions with this partner are ongoing and their management has shared with us that they have a budget meeting scheduled for Wednesday, December 18th. The partner will reach out to us to share their initial thoughts and next steps – we have been informed that final decisions would be made at their January board meeting.
Further, BioElectronics is also in discussion (under an NDA) with a global player in the orthopedic devices industry that specializes in products for rehabilitation, pain therapy, physical therapy, and surgical reconstructive implants. Our intended relationship is as an OEM supplier where, the partner would use ActiPatch technology to differentiate their line of products in the marketplace. They will contribute significant assets for promotional activities of the product, including a direct-sales team of several hundred. The initial contract proposal is for the North American territory and is expected to generate more than $2 million in sales for BioElectronics, in 2020.[Orthopedic Partnership #2]
One of our SDVOSB partners has made progress with a member of the Department of Defense's Clinical Medical Research team. This individual will begin a new position as the Director of Complimentary and Interventional Pain Management at NIH's Non-Pharmacological Pain Management Interventions program in January 2020. We anticipate being able to set up a meeting in February 2020.
E & E Communications Mon, Jan 6
Within the US market, we plan on utilizing this strategy to increase brand exposure in both OTC (musculoskeletal pain conditions) and prescription (post-operative pain conditions) categories. The ongoing proposals with two major partners are progressing briskly, and we anticipate being able to finalize them in mid to late January.
we are investigating an opportunity to renew sales in the UK with the help of a US-based partner who has strong relationships in the UK retail market.
E & E Communications Mon, Jan 20
USA Channel Partners Update
There are three potential channel partners with whom the Company has signed non-disclosure agreements (NDAs):
1· The first channel partner, who is dominant in the OTC footcare market, has indicated that a business proposal, for licensing the plantar fasciitis market, will be discussed at their board meeting on Thursday, January 23. The expectation has been set that discussions with BIEL towards finalizing a deal will take place following this meeting.
2· The second channel partner, who is a key player in the global orthopedic appliances market, has indicated that a business proposal is being verified by their legal department. The expectation is that this proposal, spanning licensing for a multitude of musculoskeletal conditions, will be sent to BIEL in January, following which a deal will be finalized.
3· The third channel partner, who is a key player in the global chronic wound management market, has requested that a teleconference, originally scheduled for Friday, January 17 be rescheduled to Friday, January 31. The expectation is to undertake discussions towards establishing a strategic alliance and introducing innovative electroceutical products to the market.
E & E Communications Tue, Feb 18
Previously, BIEL informed the investor community that non-disclosure agreements (NDAs) were in place with three potential channel partners, specializing in the footcare, orthopedic appliances and wound care management categories respectively.
Discussions are ongoing with the footcare and orthopedic companies, while the conference call on January 31 with the wound care management company went exceptionally well. We are working towards establishing a strategic relationship with the latter company.
E & E Communications Mon, Sep 16, 2019
We are also finalizing product packaging configuration with the largest distributor of chiropractic products in US. They have access to 80% of the 70,000 chiropractors in the US who treat 35 million patients annually.
We remain in discussions with several marketers of wraps and braces for the sports and retail markets. The next several months are key to obtain inclusion in the 2020 sales plans and shelf space.
US OTC Sales and Marketing Partnership
We will begin meeting with our partner to design and finalize the development of our orthopedic line to be sold into performance health and other drug distributors. This has been finalized and we are looking forward towards immediate retail sales of which we have gotten our first purchase order from today.
E & E Communications Mon, Nov 4, 2019
We have actively re-engaged discussions with companies who previously expressed interest in establishing commercial partnerships with BioElectronics, in the US. We have had a face to face discussion with a major company that has a primary interest in plantar fasciitis. The discussion went very well, with further meetings already scheduled. We have also scheduled calls with two large players in the commercial space.
One of our channel partners has finalized a deal with an American multinational health care services company to place ActiPatch in 1,000 independently owned stores and launch under an initiative for alternative pain therapies. This program is set to launch late in the first quarter of 2020. Our channel partner has expertise in creating custom orthopedic appliances and has been asked by a global provider of high-quality orthopedic devices to develop a product for proposed post-operative use, and two other anatomical sites which fall under existing OTC indications.
We have also begun recruiting established Veteran Owned Small Business organizations that are currently selling medical products to the Veterans Administration Health System. At this time, we have signed agreements with two organizations.
E & E Communications Mon Mon, Dec 16, 2019
In early November we entered into an NDA with one such partner. The NDA discussions with this partner are ongoing and their management has shared with us that they have a budget meeting scheduled for Wednesday, December 18th. The partner will reach out to us to share their initial thoughts and next steps – we have been informed that final decisions would be made at their January board meeting
Further, BioElectronics is also in discussion (under an NDA) with a global player in the orthopedic devices industry that specializes in products for rehabilitation, pain therapy, physical therapy, and surgical reconstructive implants. Our intended relationship is as an OEM supplier where, the partner would use ActiPatch technology to differentiate their line of products in the marketplace. They will contribute significant assets for promotional activities of the product, including a direct-sales team of several hundred. The initial contract proposal is for the North American territory and is expected to generate more than $2 million in sales for BioElectronics, in 2020.[Orthopedic Partnership #2]
one of our SDVOSB partners has made progress with a member of the Department of Defense's Clinical Medical Research team. This individual will begin a new position as the Director of Complimentary and Interventional Pain Management at NIH's Non-Pharmacological Pain Management Interventions program in January 2020. We anticipate being able to set up a meeting in February 2020.
E & E Communications Mon, Jan 6
Within the US market, we plan on utilizing this strategy to increase brand exposure in both OTC (musculoskeletal pain conditions) and prescription (post-operative pain conditions) categories. The ongoing proposals with two major partners are progressing briskly, and we anticipate being able to finalize them in mid to late January.
we are investigating an opportunity to renew sales in the UK with the help of a US-based partner who has strong relationships in the UK retail market.
E & E Communications Mon, Jan 20
USA Channel Partners Update
There are three potential channel partners with whom the Company has signed non-disclosure agreements (NDAs):
· The first channel partner, who is dominant in the OTC footcare market, has indicated that a business proposal, for licensing the plantar fasciitis market, will be discussed at their board meeting on Thursday, January 23. The expectation has been set that discussions with BIEL towards finalizing a deal will take place following this meeting.
· The second channel partner, who is a key player in the global orthopedic appliances market, has indicated that a business proposal is being verified by their legal department. The expectation is that this proposal, spanning licensing for a multitude of musculoskeletal conditions, will be sent to BIEL in January, following which a deal will be finalized.
· The third channel partner, who is a key player in the global chronic wound management market, has requested that a teleconference, originally scheduled for Friday, January 17 be rescheduled to Friday, January 31. The expectation is to undertake discussions towards establishing a strategic alliance and introducing innovative electroceutical products to the market.
E & E Communications Tue, Feb 18
Previously, BIEL informed the investor community that non-disclosure agreements (NDAs) were in place with three potential channel partners, specializing in the footcare, orthopedic appliances and wound care management categories respectively. Discussions are ongoing with the footcare and orthopedic companies, while the conference call on January 31 with the wound care management company went exceptionally well. We are working towards establishing a strategic relationship with the latter company.
Mon, Jun 17, 2019
Walmart for its annual supplier’s orientation meeting this week. ActiPatch is one of 30 products that were selected by the pain category manager at Walmart,
MundiPharma subsidiary to expand our successful relationship with Mundipharma Australia/New Zealand/South East Asia, which would raise the total coverage under Mundipharma to territories 20 countries.
Sep 16, 2019
distributor of chiropractic products in US with 70,000 chiropractors in the US
several marketers of wraps and braces for the sports and retail markets
Partner # 2: orthopedic line to be sold into performance health and other drug distributors. This has been finalized and we are looking forward towards immediate retail sales of which we have gotten our first purchase order from today.
Nov 4, 2019
Partner # 1: major company that has a primary interest in plantar fasciitis.
two large players in the commercial space.
Partner # 2: global orthopedic appliances
Partner # 3: : prescription (post-operative pain conditions)
an American multinational health care services company to place ActiPatch in 1,000 independently owned stores and launch under an initiative for alternative pain therapies. This program is set to launch late in the first quarter of 2020.
Partner # 2: global provider of high-quality orthopedic devices
Veteran Owned Small Business organizations
Dec 16, 2019
Partner # 2: global player in the orthopedic devices industry that specializes in products for rehabilitation, pain therapy, physical therapy, and surgical reconstructive implants. is expected to generate more than $2 million in sales for BioElectronics, in 2020.[Orthopedic Partnership #2]
Jan 6
Partner # 2: OTC (musculoskeletal pain conditions) major partner, we anticipate being able to finalize proposal in mid to late January.
Partner # 3: prescription (post-operative pain conditions) major partner, we anticipate being able to finalize proposal in mid to late January.
renew sales in the UK with the help of a US-based partner
Jan 20
three potential channel partners
1. footcare, - board meeting on Thursday, January 23. The expectation has been set that discussions with BIEL towards finalizing a deal will take place following this meeting.
2. global orthopedic appliances market, licensing for a multitude of musculoskeletal conditions, will be sent to BIEL in January, following which a deal will be finalized.
3. wound care management -
Feb 18
three potential channel partners
1. footcare, Discussions are ongoing
2. global orthopedic appliances Discussions are ongoing
3. wound care management working towards establishing a strategic relationship
